19
May

Just months after inking a $246 million development deal with Baxter for a biosimilar of Enbrel, Redwood City, CA-based Coherus has rounded up a whopping $55 million C round, including cash from KKR.

…read more

Source: KKR steps in to back $55M C round for biosimilars developer Coherus

    

0 No comments